2Suppliers
1Customers
3Debt Items
0Related Chains

Omeros Corporation Suppliers

TickerNameConfidenceEvidence
LONZA-BIOLOGICS-TUAS-PTE-LTD LONZA-BIOLOGICS-TUAS-PTE-LTD 92% In July 2019, we entered into a master services agreement with Lonza Biologics Tuas Pte. Ltd. ("Lonza") for the commercial production of YARTEMLEA
NOVO-NORDISK NOVO-NORDISK 90% Under the Transition Services Agreement, we are transitioning to Novo Nordisk certain agreements and relationships with third parties that manufacture, store, and distribute zaltenibart for use in pr…

Omeros Corporation Customers

TickerNameConfidenceEvidence
NOVO-NORDISK NOVO-NORDISK 90% The APLA with Novo Nordisk includes variable consideration in the form of milestone payments that are contingent upon the achievement of specified development, regulatory or commercialization events

Omeros Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
OMER-DEBT Debt stack $226.6M 90% Market cache reports total debt of $226.6M.
OMER-DEBT-11515 Warrants outstanding: 200000 90% xbrl warrant detail from xbrl 2023-04-12.
OMER-DEBT-11516 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Omeros Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Omeros Corporation.

Omeros Corporation Ownership

HolderNameConfidenceEvidence
OMER-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 162 tracked holders.

Omeros Corporation Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.